MetaCap

Optimi Health (OPTH) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Optimi Health is the larger company by market cap ($8.6 million vs $8.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OPTH-75.16%PTN-68.61%
+6%-37%-79%
May 20, 20261 yearNov 20, 2026
OPTH-74.19%PTN-69.22%
+6%-36%-78%
May 18, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OPTH versus PTN key metrics
MetricOPTHPTN
Share price$1.51$4.58
Market cap$8.65M$8.16M
1-day change-13.71%-7.10%
YTD return—-70.22%
1-year return—-79.93%
5-year return—-99.35%
EPS (TTM)$-1.56$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.83M
Net income (latest FY)—$-8.38M
Operating margin—-98.17%
Net margin—-94.88%
52-week high$6.40$31.00
52-week low$1.51$4.51
Distance from 52-week high-76.41%-85.23%
Analyst consensus—strong_buy
Avg. price target upside—+1068.12%
Average volume43.55K71.93K
Shares outstanding5.73M1.78M
Employees—25
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Optimi Health

OPTH stock →

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

OPTH vs PTN FAQ

Which is bigger, Optimi Health or Palatin Technologies?

Optimi Health (OPTH) is larger, with a market capitalization of $8.65M compared with $8.16M for Palatin Technologies (PTN).

Are Optimi Health and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons